Conor McClune

@cmcclune.bsky.social

Plants, specialized metabolism, synthetic biology, protein evolution, and everything in between. Postdoc at Sattley & Fordyce Labs, Stanford Previously SynBio @ Voigt & Laub Labs, MIT

Reminiscing about the fantastic 4th SBNP Conference in 2024! 📢 Interested in joining us for the 5th edition? Visit the conference website today to secure your place at the best available price. We look forward to welcoming you later this year 🎉 Conference Website: bit.ly/3OX3KEM

Bild

Lovely C&EN @cenmag.bsky.social story on the history and personal impact of the cancer drug Taxol. After spending recent years deciphering how yew trees, our source for Taxol, synthesize this lifesaving drug, it’s so nice to see it in the larger context #secmet #medsky Plants are amazing chemists.

Paclitaxel saved my life. New discoveries could boost supply

After decades, scientists have finally pieced together the 23-step biosynthetic pathway to produce this cancer drug

cen.acs.org

Do you know what happens when you touch a carnivorous sundew plant? If the touch is strong and large enough, a cytosolic calcium wave will spread from the site of touch throughout the whole plant, but if you only touch one tentacle (see post below), the calcium wave will be local and less intense.

Scientists, please take a moment to comment on these plans to limit animal testing in drug regulation and biomedical research. Use whatever experience you have to make your comments specific to you. The law requires regulators take these comments into account, so it might help. Mine is attached.

I am a full professor of pediatrics at the University of Chicago, and a world renowned expert in artificial intelligence and molecular biology, particularly AI and drug discovery.  I obtained a Ph.D. in artificial intelligence (computer science) from Yale University in 1989, was a staff scientist at NIH from 1989 to 2000, when I moved to the University of Colorado School of Medicine to become a professor of Pharmacology. I have published more than 200 scientific papers and hold two US patents.  In addition to my faculty position, I am also the chief technology officer of TenZero Biosciences, an early stage drug discovery company.  Not incidental to this letter, I am also a frequent volunteer participant (subject) in clinical trials. 

I have spent my career trying to create artificial intelligence systems that facilitate the discovery of new pharmaceuticals.  In 2003, I won the American Association for Artificial Intelligence's Engelmore Prize for Innovative Applications of AI for my work in AI and molecular biology.  In that talk, I proposed a better version of the "Turing Test" for whether a computer system is actually intelligent would be one getting credit for inventing a new drug.  We are quite close to that mark now, with InSilico's Rentosertib in phase II trials. I am proud of our industry's ability to realize that vision from 20 years ago, and of my small part in that progress.   

The excitement of the first AI-discovered drug is wonderful, but should not be taken as evidence that AI is ready to usurp the FDA's traditional regulatory role. Even under the current very stringent regulatory scrutiny, mistakes are made that cost lives. Rofecoxib is perhaps the most obvious example, but there are of course many others.  There are many published methods to assess the safety of novel compounds for human beings, including ones based on AI.  However, none of them are perfect. The complexity and diversity of human biology means that the effects of novel compounds on …
John Wallingford@jbwallingford.bsky.social · last yr.

The NIH is asking scientists and the public to comment on plans to drastically limit animal model research. If you think animal models remain important tools for basic and clinical research tell them! Click the link below and scroll down to send your comments! www.fda.gov/news-events/...

I just learned these this elephant-trunked-shaped cells, known as ciliate, put their sexy DNA into a special pocket (called a generative nucleus), and the rest of their DNA in a normal get-shit-done nucleus. It has functional specialization nuclei. Respectfully: holy shit 🧵🧪

Bild

It makes sense that skin microbes would have an intimate relationship with our immune cells. But engineering these bugs into topical vaccines still feels like sci-fi. Congrats @djenetbousbaine.bsky.social on the well deserved prize

Djenet Bousbaine@djenetbousbaine.bsky.social · last yr.

It’s truly an honor to receive this year’s @science.org Noster Microbiome prize. Here’s my essay on how we can engineer skin microbes to build topical vaccines: